4.4 Article

Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults

期刊

DRUG AND ALCOHOL DEPENDENCE
卷 112, 期 1-2, 页码 39-45

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2010.05.010

关键词

Cannabis use disorder; Major depressive disorder; Fluoxetine; Cognitive behavioral therapy; Motivation enhancement therapy

资金

  1. National Institute on Drug Abuse [R01 DA019142, R01 DA14635, R01 DA019142-S1, P50 DA05605]
  2. NIDA Clinical Trials Network
  3. National Institute on Alcohol Abuse and Alcoholism [R01 AA015173, R01 AA14357, R01 AA13397, R21 AA016272, U01 AA016482, K24 AA15320, K02 AA000291]
  4. Veterans Affairs MIRECC
  5. [K02 DA017822]

向作者/读者索取更多资源

Objective: This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the cannabis use of adolescents and young adults with comorbid major depression (MDD) and a cannabis use disorder (CUD) (cannabis dependence or cannabis abuse). We hypothesized that fluoxetine would demonstrate efficacy versus placebo for the treatment of the depressive symptoms and the cannabis use of adolescents and young adults with comorbid MDD/CUD. Methods: We conducted the first double-blind placebo-controlled study of fluoxetine in adolescents and young adults with comorbid MDD/CUD. All participants in both treatment groups also received manual-based cognitive behavioral therapy (CBT) and motivation enhancement therapy (MET) during the 12-week course of the study. Results: Fluoxetine was well tolerated in this treatment population. No significant group-by-time interactions were noted for any depression-related or cannabis-use related outcome variable over the 12-week study. Subjects in both the fluoxetine group and the placebo group showed significant within-group improvement in depressive symptoms and in number of DSM diagnostic criteria for a CUD. Large magnitude decreases in depressive symptoms were noted in both treatment groups, and end-of-study levels of depressive symptoms were low in both treatment groups. Conclusions: Fluoxetine did not demonstrate greater efficacy than placebo for treating either the depressive symptoms or the cannabis-related symptoms of our study sample of comorbid adolescents and young adults. The lack of a significant between-group difference in these symptoms may reflect limited medication efficacy, or may result from efficacy of the CBT/MET psychotherapy or from limited sample size. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据